Efficacy and Safety of Pembrolizumab for Gemcitabine/Cisplatin-Refractory Biliary Tract Cancer: A Multicenter Retrospective Study

Pembrolizumab, an anti-programmed cell death (PD)-1 monoclonal antibody, is an anticancer agent showing substantial benefit in lung cancer and melanoma treatment. Biliary tract cancer (BTC) has been shown to respond to pembrolizumab; however, no credible data of such treatment outcomes exist. Theref...

Full description

Saved in:
Bibliographic Details
Published in:J Clin Med
Main Authors: Lee, Sang Hoon, Lee, Hee Seung, Lee, Sang Hyub, Woo, Sang Myung, Kim, Dong Uk, Bang, Seungmin
Format: Artigo
Language:Inglês
Published: MDPI 2020
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7355970/
https://ncbi.nlm.nih.gov/pubmed/32517311
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm9061769
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items